Key Highlights:
- Kuala Lumpur-based private equity firm Creador is in advanced talks to acquire around a 10% stake in Leeford Healthcare for nearly ₹800 crore, valuing the Ludhiana-based pharmaceutical company at ₹8,000–8,500 crore ($900 million). If completed, the deal would mark Leeford’s first external equity investment since its founding in 2006.
- Promoted by Jiwan Lal Gupta, Leeford Healthcare has a portfolio of 2,000+ products spanning prescription medicines, generic formulations, nutraceuticals, personal care, specialty therapies, and mobility aids. The company operates 10 manufacturing facilities and an in-house formulation and development center in Himachal Pradesh, while exporting products to multiple international markets.
- Leeford reported 5% revenue growth to $204.7 million in FY25, alongside a 27% increase in net profit to $28.4 million and a 24% rise in EBITDA to $40.5 million, according to Tracxn. The investment follows Creador’s November 2025 acquisition of a nearly 7% stake in La Renon Healthcare, further expanding its presence in India’s pharmaceutical sector.
Implications:
If completed, the transaction would likely be a strong validation event for mid-sized Indian pharmaceutical businesses that combine branded generics, nutraceuticals, and specialty products with in-house manufacturing, because a ₹8,000–₹8,500 crore valuation for a first-time external equity round signals that profitable, founder-led companies can still attract premium private-equity capital. It would also deepen Creador’s footprint in Indian healthcare after its La Renon investment, suggesting a strategy of backing scaled domestic pharma names with room for international growth, and may increase competitive pressure on similar private companies to professionalize governance and pursue institutional capital for expansion.
Source: ET Pharma
